8-methyl-7-(prop-1-yn-1-yl)-2-((pyrimidin-2-ylthio)methyl)quinazolin-4(3H)-one

ID: ALA5191676

PubChem CID: 137701959

Max Phase: Preclinical

Molecular Formula: C17H14N4OS

Molecular Weight: 322.39

Names and Identifiers

Canonical SMILES:  CC#Cc1ccc2c(=O)[nH]c(CSc3ncccn3)nc2c1C

Standard InChI:  InChI=1S/C17H14N4OS/c1-3-5-12-6-7-13-15(11(12)2)20-14(21-16(13)22)10-23-17-18-8-4-9-19-17/h4,6-9H,10H2,1-2H3,(H,20,21,22)

Standard InChI Key:  VRECINGNBPANGK-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   -2.1413    0.6180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4267    1.0303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7148    0.6185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7148   -0.2067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4249   -0.6183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1413   -0.2104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0002    1.0310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7144    0.6183    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7144   -0.2067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0002   -0.6192    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0002    1.8562    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4290   -0.6192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1436   -0.2067    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.8583   -0.6192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4249   -1.4435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8559   -0.6229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5706   -1.0355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2852   -1.4481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5731   -0.2069    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2852   -0.6189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2852   -1.4443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5748   -1.8562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8583   -1.4480    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  3  7  1  0
  8  7  1  0
  9  8  1  0
 10  9  2  0
  4 10  1  0
  7 11  2  0
  9 12  1  0
 12 13  1  0
 13 14  1  0
  5 15  1  0
  6 16  1  0
 16 17  3  0
 17 18  1  0
 19 14  2  0
 20 19  1  0
 21 20  2  0
 22 21  1  0
 23 22  2  0
 14 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5191676

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 322.39

Molecular Weight (Monoisotopic): 322.0888

AlogP: 2.69

#Rotatable Bonds: 3

Polar Surface Area: 71.53

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.76

CX Basic pKa: 3.24

CX LogP: 3.02

CX LogD: 3.02

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.46

Np Likeness Score: -1.31

References

1. Nizi MG, Maksimainen MM, Murthy S, Massari S, Alaviuhkola J, Lippok BE, Sowa ST, Galera-Prat A, Prunskaite-Hyyryläinen R, Lüscher B, Korn P, Lehtiö L, Tabarrini O..  (2022)  Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.,  237  [PMID:35500474] [10.1016/j.ejmech.2022.114362]

2. Nizi MG, Maksimainen MM, Lehtiö L, Tabarrini O..  (2022)  Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.,  65  (11.0): [PMID:35608571] [10.1021/acs.jmedchem.2c00281]

Source

Source(1):

• Scientific Literature